• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Osmotica Pharmaceuticals plc (Amendment)

    4/29/21 4:49:41 PM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OSMT alert in real time by email
    SC 13G/A 1 osmt0429sch13ga.htm SCHEDULE 13G (AMENDMENT NO. 1)

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934 (Amendment No. 1)

    Osmotica Pharmaceuticals plc
    (Name of Issuer)

     

    Ordinary Shares, nominal value $0.01 per share
     

     

    G6S41R101
    (CUSIP Number)

     

    Orbit Co-Invest I, LLC

    c/o Paradox Capital Partners, LLC

    1500 East Las Olas Blvd,

    Suite 200

    Ft. Lauderdale, FL 33301

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    April 1, 2021
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    |_| Rule 13d-1(b)

    |X| Rule 13d-1(c)

    |_| Rule 13d-1(d)

     

     

     

     

     

     

       

     

    SCHEDULE 13G

    CUSIP No. G6S41R101

     

     

     

    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
    Orbit Co-Invest I, LLC
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)  [ ]

    (b)  [ ]

    3 SEC USE ONLY
     
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH
    5 SOLE VOTING POWER  
    0  
    6 SHARED VOTING POWER  
       
    7 SOLE DISPOSITIVE POWER  
    0  
    8 SHARED DISPOSITIVE POWER  
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)
          [   ]
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0
    12 TYPE OF REPORTING PERSON (See Instructions)
    OO
             
     
     

    Explanatory Note:

    This Amendment No. 1 amends in its entirety the statement on Schedule 13G originally filed on November 27, 2020 by the Reporting Person. On March 31, 2021 the Reporting Person distributed all of the Ordinary Shares of the Issuer to SDK VC Pharma Holding Corp., the sole member of the Reporting Person, which entity elected to dissolve and simultaneously distributed the Ordinary Shares to its members.

    Item 1 (a). Name of Issuer: Osmotica Pharmaceuticals plc

    Item 1 (b). Address of Issuer’s Principal Executive Offices:

     

    Osmotica Pharmaceuticals plc

    400 Crossing Boulevard

    Bridgewater, NJ 08807

    Item 2. (a). Name of Person Filing: Orbit Co-Invest I, LLC

    Item 2. (b). Address of Principal Business Office:

     

    Orbit Co-Invest I, LLC

    c/o Paradox Capital Partners, LLC

    1500 East Las Olas Blvd.

    Suite 200

    Ft. Lauderdale, Fl. 33301

    Item 2. (c). Citizenship: Delaware

    Item 2. (d). Title of Class of Securities: Ordinary Shares

    Item 2. (e). CUSIP Number: G6S41R101

    Item 3.If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), or (c), check whether person filing is a:
      (a) |_| Broker or dealer registered under Section 15 of the Act.
      (b) |_| Bank as defined in Section 3(a)(6) of the Act.
      (c) |_| Insurance company as defined in Section 3(a)(19) of the Act.
      (d) |_| Investment company registered under Section 8 of the Investment Company Act.
      (e) |_| An investment adviser in accordance with Rule 13d-1(b)(1) (ii)(E);
      (f) |_| An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
      (g) |_| A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) |_| A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
      (i) |_| A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
     

    (j)

     

    (k)

    |_|

     

    |_|

    A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

     

    Group, in accordance with Rule 13d-1(b)(1)(ii)(J)

    Item 4.Ownership.

    (a).       Amount beneficially owned: 0

    (b)       Percent of Class: 0

    (c)       Number of shares as to which such person has:

    (i)       Sole power to vote or to direct the vote: 0

    (ii)       Shared power to vote or to direct the vote:

    (iii)       Sole power to dispose or to direct the disposition of: 0

    (iv)       Shared power to dispose or to direct the disposition of:

    Item 5.Ownership of 5 Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following |_|.
    Item 6.Ownership of More than 5 Percent on Behalf of Another Person: Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person: Not Applicable
    Item 8.Identification and Classification of Members of the Group: Not Applicable.
    Item 9.Notice of Dissolution of Group: Not Applicable.

    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Signature.

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    April 29, 2021  
    Dated  
    /s/ Harvey Kesner  
    Signature  
    Harvey Kesner, Manager  
    Name/Title  

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

    Get the next $OSMT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSMT

    DatePrice TargetRatingAnalyst
    12/23/2021$5.00Buy
    HC Wainwright & Co.
    11/9/2021$7.00Buy
    Jefferies
    9/24/2021$6.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $OSMT
    SEC Filings

    View All

    Osmotica Pharmaceuticals plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - RVL Pharmaceuticals plc (0001739426) (Filer)

    1/19/22 7:07:09 AM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Osmotica Pharmaceuticals plc filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - Osmotica Pharmaceuticals plc (0001739426) (Filer)

    1/18/22 8:16:54 AM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Osmotica Pharmaceuticals plc

    EFFECT - Osmotica Pharmaceuticals plc (0001739426) (Filer)

    12/10/21 12:15:30 AM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on Osmotica Pharmaceuticals with a new price target

    HC Wainwright & Co. initiated coverage of Osmotica Pharmaceuticals with a rating of Buy and set a new price target of $5.00

    12/23/21 6:10:29 AM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Osmotica Pharmaceuticals with a new price target

    Jefferies resumed coverage of Osmotica Pharmaceuticals with a rating of Buy and set a new price target of $7.00

    11/9/21 9:18:42 AM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Osmotica Pharmaceuticals with a new price target

    Cantor Fitzgerald initiated coverage of Osmotica Pharmaceuticals with a rating of Overweight and set a new price target of $6.00

    9/24/21 7:18:43 AM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Schaub James bought $100,366 worth of Ordinary Shares (93,800 units at $1.07), increasing direct ownership by 30% to 405,900 units

    4 - Osmotica Pharmaceuticals plc (0001739426) (Issuer)

    12/20/21 5:03:41 PM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Devries Tina Marie

    4 - Osmotica Pharmaceuticals plc (0001739426) (Issuer)

    11/8/21 4:09:19 PM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Schaub James

    4 - Osmotica Pharmaceuticals plc (0001739426) (Issuer)

    11/8/21 4:07:59 PM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSMT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol "RVLP," Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance

    -- Fourth Quarter 2021 net sales for UPNEEQ grew by approximately 41% to $3.1 million compared to the third quarter 2021 -- -- Fourth Quarter 2022 net sales for UPNEEQ targeted to range from $20-$25 million -- -- Full national launch into medical aesthetics expected to commence in February 2022 -- -- Company to host video webcast at 8:30am ET on January 19, 2022 -- BRIDGEWATER, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("OSMT" or the "Company"), a specialty pharmaceutical company, announced today that the Company has changed its name to RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL"). This rebranding reflects RVL's strategy to become a growth comp

    1/19/22 6:50:00 AM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022

    -- Topics include corporate name change, launch plans into the medical aesthetics market and general business updates -- -- Featured speakers include Dr. Jackie Yee and Dr. Justin Harper -- Bridgewater, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer and James "JD" Schaub, Chief Operating Officer, will host a video webcast to discuss recent UPNEEQ® trends, pending expansion into the medical aesthetics market and other general business updates. Dr. Jackie Yee is board-certified in Plastic and Reconstructive Surgery and speciali

    1/18/22 6:50:00 AM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022

    BRIDGEWATER, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and other key speakers, will host a call to discuss recent UPNEEQ® trends, pending expansion into the medical Aesthetics market and other general business updates as follows: Date:Wednesday, January 19, 2022Time:8:30 a.m. ETWebcast:https://experience.v-unite.com/#/aestheticrecorddemo/rvlinvestorday/room/welcome The webcast will be available thereafter via the Company's website at www.rvlpharma.com under the "Investor & News

    1/6/22 8:55:37 AM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSMT
    Financials

    Live finance-specific insights

    View All

    Osmotica Pharmaceuticals plc to Provide Third Quarter 2021 Business and Financial Update on November 15, 2021

    BRIDGEWATER, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a specialty pharmaceutical company, today announced that the Company will release its 2021 third quarter financial results on Monday, November 15, 2021, after the close of the U.S. financial markets. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows: DateMonday, November 15, 2021Time4:30 p.m. ETToll free (U.S.)(866) 672-5029International(409) 217-8312Conference ID57399556Webcast (live and replay)www.osmotica.com under the "Investor & News" section

    11/11/21 7:30:00 PM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Osmotica Pharmaceuticals plc to Provide Second Quarter 2021 Business and Financial Update on August 16, 2021

    BRIDGEWATER, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (NASDAQ:OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, today announced that the Company will release its 2021 second quarter financial results on Monday, August 16, 2021, after the close of the U.S. financial markets. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will host a conference call as follows: Date  Monday, August 16, 2021Time 4:30 p.m. ETToll free (U.S.) (866) 672-5029International  (409) 217-8312Conference ID 1278168Webcast (live and replay) www.osmotica.com under the "Investor &

    8/11/21 7:00:00 PM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OSMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Osmotica Pharmaceuticals plc (Amendment)

    SC 13D/A - Osmotica Pharmaceuticals plc (0001739426) (Subject)

    11/3/21 4:30:31 PM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Osmotica Pharmaceuticals plc

    SC 13G - Osmotica Pharmaceuticals plc (0001739426) (Subject)

    10/22/21 4:27:53 PM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Osmotica Pharmaceuticals plc (Amendment)

    SC 13D/A - Osmotica Pharmaceuticals plc (0001739426) (Subject)

    10/14/21 4:10:18 PM ET
    $OSMT
    Biotechnology: Pharmaceutical Preparations
    Health Care